Latest Ratios: P/E Ratio -7.1x · EV/EBITDA 8.1x · ROE -5.4%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $11M | $14M | $21M | $15M | $18M | $14M | $14M | $14M | $14M | $15M | $18M |
| Enterprise Value | $30M | $33M | $34M | $19M | $20M | $24M | $24M | $29M | $33M | $36M | $42M |
| P/E Ratio → | -7.13 | — | 9.67 | 24.95 | 13.95 | 74.06 | — | 10.17 | 14.00 | 7.87 | 19.71 |
| P/S Ratio | 0.39 | 0.50 | 0.75 | 0.71 | 0.94 | 0.81 | 0.77 | 0.70 | 0.73 | 0.77 | 0.98 |
| P/B Ratio | 0.39 | 0.50 | 0.71 | 0.58 | 0.72 | 0.59 | 0.58 | 0.38 | 0.39 | 0.42 | 0.56 |
| P/FCF | — | — | — | — | 2.70 | 3.13 | 1.48 | 2.05 | 2.21 | 2.15 | 2.71 |
| P/OCF | 0.00 | 0.00 | 128.04 | 2.66 | 2.55 | 2.29 | 1.41 | 1.80 | 1.78 | 1.93 | 2.19 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.18 | 1.19 | 0.90 | 1.04 | 1.34 | 1.35 | 1.42 | 1.68 | 1.85 | 2.27 |
| EV / EBITDA | 8.11 | 8.95 | 9.97 | 3.53 | 2.71 | 3.57 | — | 10.14 | 3.81 | 3.97 | 4.42 |
| EV / EBIT | — | — | 12.28 | 10.60 | 6.15 | 14.05 | — | 10.20 | 9.46 | 8.32 | 8.51 |
| EV / FCF | — | — | — | — | 2.99 | 5.16 | 2.60 | 4.13 | 5.10 | 5.12 | 6.28 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 18.0% | 18.0% | 32.4% | 43.8% | 42.4% | 38.2% | 25.0% | 33.6% | 38.0% | 44.3% | 47.0% |
| Operating Margin | -7.2% | -7.2% | -9.9% | 1.3% | 12.3% | 7.7% | -53.1% | -22.0% | 9.4% | 12.3% | 17.6% |
| Net Profit Margin | -5.5% | -5.5% | 7.7% | 2.9% | 6.7% | 1.1% | -39.6% | 3.2% | 5.2% | 9.8% | 5.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -5.4% | -5.4% | 7.8% | 2.4% | 5.3% | 0.8% | -23.1% | 1.8% | 2.8% | 5.6% | 2.9% |
| ROA | -2.7% | -2.7% | 4.0% | 1.3% | 3.0% | 0.4% | -14.5% | 1.2% | 1.8% | 3.2% | 1.6% |
| ROIC | -3.4% | -3.4% | -5.8% | 0.7% | 6.0% | 3.0% | -16.4% | -6.3% | 2.5% | 3.2% | 4.6% |
| ROCE | -4.9% | -4.9% | -6.4% | 0.7% | 6.2% | 3.8% | -24.6% | -9.7% | 3.8% | 4.8% | 6.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.82 | 0.82 | 0.77 | 0.67 | 0.56 | 0.72 | 0.61 | 0.44 | 0.55 | 0.64 | 0.82 |
| Debt / EBITDA | 6.11 | 6.11 | 6.89 | 3.25 | 1.90 | 2.63 | — | 5.73 | 2.32 | 2.55 | 2.81 |
| Net Debt / Equity | — | 0.69 | 0.41 | 0.15 | 0.08 | 0.38 | 0.44 | 0.39 | 0.51 | 0.58 | 0.74 |
| Net Debt / EBITDA | 5.18 | 5.18 | 3.62 | 0.73 | 0.26 | 1.41 | — | 5.11 | 2.16 | 2.31 | 2.51 |
| Debt / FCF | — | — | — | — | 0.29 | 2.03 | 1.12 | 2.08 | 2.89 | 2.98 | 3.57 |
| Interest Coverage | -1.28 | -1.28 | 1.83 | 1.63 | 4.12 | 2.27 | -7.94 | 2.17 | 2.14 | 2.25 | 2.93 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.76 | 0.76 | 2.52 | 1.90 | 3.62 | 2.56 | 0.88 | 1.31 | 1.05 | 0.99 | 0.97 |
| Quick Ratio | 0.76 | 0.76 | 2.52 | 1.90 | 3.62 | 2.56 | 0.88 | 1.31 | 1.05 | 0.95 | 0.94 |
| Cash Ratio | 0.15 | 0.15 | 1.06 | 1.27 | 2.38 | 1.38 | 0.32 | 0.17 | 0.15 | 0.24 | 0.33 |
| Asset Turnover | — | 0.51 | 0.47 | 0.44 | 0.45 | 0.39 | 0.41 | 0.38 | 0.34 | 0.34 | 0.31 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 31.12 | 39.62 |
| Days Sales Outstanding | — | 171.85 | 163.09 | 82.96 | 76.31 | 99.88 | 93.62 | 125.11 | 127.34 | 97.71 | 85.39 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 10.3% | 4.0% | 7.2% | 1.4% | — | 9.8% | 7.1% | 12.7% | 5.1% |
| FCF Yield | — | — | — | — | 37.1% | 32.0% | 67.7% | 48.8% | 45.3% | 46.6% | 36.9% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $7M | $7M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $5M |
Liquidity and capital intensity
Based on current market data, AMS trades at a P/S ratio of 0.39, which, according to recent financial filings, suggests the market is pricing in significant long-term terminal value risk rather than the potential upside of its specialized radiotherapy joint ventures.
The depressed P/B ratio of 0.39 indicates that the market values the company's assets at a substantial discount to their book value, likely reflecting concerns over technological obsolescence. This valuation multiple implies that investors are skeptical of the company's ability to generate future returns on its existing medical equipment fleet.
As reported in quarterly financial statements, AMS has struggled to generate positive returns, with ROIC falling to -1.0% in 2026Q1, highlighting a persistent inability to compound capital effectively within its current fee-per-use clinical partnership model.
The decay in ROIC suggests that the company's investments in high-cost radiotherapy hardware are not yielding sufficient clinical utilization to cover the associated depreciation and maintenance costs. This trend warrants further investigation into whether the current asset base is fundamentally misaligned with modern oncology referral patterns.
According to recent SEC filings, the company's DSO has remained elevated, reaching 162 days in 2026Q1, which suggests that AMS faces significant challenges in converting its clinical partnership revenue into actual cash flow compared to historical performance.
The extended collection cycle implies that the company may lack sufficient leverage over its hospital partners, forcing it to absorb the working capital burden of its service model. This inefficiency exacerbates the company's liquidity constraints and limits its ability to reinvest in new technology.
Based on the latest balance sheet data, the current ratio has deteriorated sharply to 0.77 in 2026Q1, indicating that the company's short-term assets are no longer sufficient to cover its immediate obligations without potential reliance on external financing.
This liquidity profile appears increasingly vulnerable, especially given the company's high fixed-cost structure and the lumpy nature of its capital expenditure requirements. Investors should monitor whether the current cash position is sufficient to sustain operations without necessitating dilutive equity raises.
As noted in industry research, the P/E ratio is a fundamentally misapplied metric for AMS, as it obscures the company's heavy reliance on non-cash depreciation charges that do not reflect the actual economic utility of its radiotherapy equipment.
Because the company's net income is heavily impacted by the depreciation of its medical fleet, the P/E ratio fails to capture the underlying cash-generating potential of its clinical partnerships. Analysts should instead focus on EV/EBITDA or cash-flow-based metrics to better assess the company's operational viability.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AMS stock.
American Shared Hospital Services's current P/E ratio is -7.1x. The historical average is 16.9x.
American Shared Hospital Services's current EV/EBITDA is 8.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 5.4x.
American Shared Hospital Services's return on equity (ROE) is -5.4%. The historical average is 3.0%.
Based on historical data, American Shared Hospital Services is trading at a P/E of -7.1x. Compare with industry peers and growth rates for a complete picture.
American Shared Hospital Services has 18.0% gross margin and -7.2% operating margin.
American Shared Hospital Services's Debt/EBITDA ratio is 6.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.